Drug Interactions with Imaging Agents

Abstract

Drug interactions with imaging agents are an important concern in diagnostic medicine, affecting the efficacy and safety of diagnostic procedures. Imaging agents, including contrast agents used in computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), are essential for enhancing the visibility of internal structures. However, the concomitant use of pharmacological drugs can interfere with the pharmacokinetics and pharmacodynamics of these agents, leading to adverse outcomes such as nephrotoxicity, altered diagnostic results, and increased risk of complications. This review explores the mechanisms underlying drug interactions with imaging agents, including the impact of nephrotoxic drugs, drugs affecting vascular tone, and those altering the blood-brain barrier. It also discusses clinical implications and preventive strategies to minimize the risks associated with such interactions. Understanding these interactions is crucial for ensuring patient safety, improving diagnostic accuracy, and optimizing imaging outcomes in clinical settings.